Abcam returns to growth in first half with over 8% increase in constant currency revenue 11 January, 2021, Cambridge, UK - Abcam plc (AIM: ABC; Nasdaq: ABCM) ( Abcam ), a global leader in the supply of life science research tools , announces the following unaudited trading update ahead of reporting its results on 8 March 2021 for the six months ended 31 December 2020. Overall, we expect to report total first half revenue of £147.5 million (H1 2020: £138.2 million), representing growth of 8.3% on a constant currency basis and 6.7% on a reported basis. In-house products represented over 55% of total revenue and grew by over 25%. On a constant currency basis, catalogue revenue, representing 95% of the total, grew approximately 8.0% in the half whilst CP&L
Affirm Holdings Inc., which provides installment loans to online shoppers, increased the price range for its initial public offering, seeking to raise as much as $1.1 billion when it goes public this week.
ObsEva SA: ObsEva Provides Update on Yselty (Linzagolix) Clinical Development Program
- European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021
- Phase 3 EDELWEISS 3 (Conducted in Europe and US) Study of Yselty for Treatment of Endometriosis is Progressing as Planned; Primary Endpoint Readout Expected 4Q 2021
- Phase 3 EDELWEISS 2 (Conducted in the United States) Yselty Endometriosis Study Discontinued Due to Enrollment Challenges; No Safety Concerns Identified
GENEVA, Switzerland and BOSTON, MA (Jan 11, 2021) - ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women s reproductive health, today announced several important updates on its Yselty program.